个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Guo, Ye[1] * ; Shi, Mei[2] ; Yang, Ankui[3] ; Feng, Jifeng[4] ; Zhu, Xiaodong[5] ; Choi, Young-Jin[6] ; Hu, Guoqin[7] ; Pan, Jianji[8] ; Hu, Chunhong[9] ; Luo, Rongcheng[10] ; Zhang, Yiping[11] ; Zhou, Liang[12] ; Cheng, Ying[13] ; Luepfert, Christian[14] ; Cai, Junliang[15] ; Shi, yuankai[16,17,*1] ;
单位： [1]Fudan Univ, Dept Med Oncol, Shanghai Canc Ctr, Shanghai 200433, Peoples R China [2]Fourth Mil Med Univ, Dept Radiat Oncol, Xijing Hosp, Affiliated Hosp 1, Xian, Shanxi Province, Peoples R China [3]Sun Yat Sen Univ, Head & Neck Dept, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China [4]Jiangsu Canc Hosp, Dept Med Oncol, Nanjing, Jiangsu, Peoples R China [5]Guangxi Med Univ, Affiliated Canc Hosp, Dept Radiotherapy, Nanning, Guangxi Provinc, Peoples R China [6]Pusan Natl Univ Hosp, Dept Med Oncol, Busan, South Korea [7]Huazhong Univ Sci & Technol, Canc Dept, Tongji Hosp, Tongji Med Coll, Wuhan 430074, Peoples R China [8]Fujian Prov Canc Hosp, Dept Radiat Oncol, Fuzhou, Peoples R China [9]Cent S Univ, Dept Oncol, Xiangya Hosp 2, Changsha, Hunan, Peoples R China [10]Nanfang Hosp, Dept Canc Med, Guangzhou, Guangdong, Peoples R China [11]Zhejiang Canc Hosp, Chemotherapy Ctr, Hangzhou, Zhejiang, Peoples R China [12]Fudan Univ, Head & Neck Surg Dept, Eye & Ear Nose & Throat Hosp, Shanghai 200433, Peoples R China [13]Jilin Canc Hosp, Dept Med Oncol, Changchun, Jilin, Peoples R China [14]Merck KGaA, Darmstadt, Germany [15]Merck Serono Beijing Pharmaceut R&D Co, Ctr, Shanghai, Peoples R China [16]Chinese Acad Med Sci, Dept Med Oncol, Inst Canc Hosp, Beijing 100730, Peoples R China [17]Peking Union Med Coll, Beijing Key Lab Clin Study Anticancer Mol Targete, Beijing 100021, Peoples R China
出处：
DOI： 10.1002/hed.23707
ISSN：

关键词： cetuximab Chinese EXTREME trial head and neck cancer recurrent and metastatic squamous cell carcinoma

摘要：
BackgroundThe purpose of this study was to assess the efficacy, safety, and pharmacokinetics of cisplatin-based chemotherapy plus cetuximab as first-line treatment in Chinese and Korean patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). MethodsPatients (n = 68) received cetuximab weekly plus 3-week cycles of cisplatin/5-fluorouracil (5-FU) chemotherapy for up to 6 cycles. The primary endpoint was overall response rate. ResultsThe overall response rate was 55.9%, including 2 complete responses (CRs). Median overall survival (OS) was 12.6 months and median progression-free survival (PFS) was 6.6 months. Grade 3/4 adverse events (AEs) were reported in 41 (60.3%) patients. The safety profile was in line with previous clinical experience. The pharmacokinetic profile was in line with that observed with cetuximab in white and Japanese patients. ConclusionThe efficacy, safety, and pharmacokinetic findings from this study support the use of first-line platinum-based chemotherapy plus cetuximab in Chinese and Korean patients with recurrent and/or metastatic SCCHN ( NCT01177956). (c) 2014 Wiley Periodicals, Inc. Head Neck37: 1081-1087, 2015

基金：
Merck KGaA, Darmstadt, Germany
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2014]版：
大类 | 3 区 医学
小类 | 2 区 耳鼻喉科学 2 区 外科
最新[2025]版：
大类 | 3 区 医学
小类 | 2 区 耳鼻喉科学 3 区 外科
JCR分区：
出版当年[2013]版：
Q1 SURGERY Q1 OTORHINOLARYNGOLOGY
最新[2023]版：
Q1 OTORHINOLARYNGOLOGY Q1 SURGERY

影响因子： 最新[2023版] 最新五年平均 出版当年[2013版] 出版当年五年平均 出版前一年[2012版] 出版后一年[2014版]

第一作者：
第一作者单位： [1]Fudan Univ, Dept Med Oncol, Shanghai Canc Ctr, Shanghai 200433, Peoples R China
通讯作者：
通讯机构： [16]Chinese Acad Med Sci, Dept Med Oncol, Inst Canc Hosp, Beijing 100730, Peoples R China [17]Peking Union Med Coll, Beijing Key Lab Clin Study Anticancer Mol Targete, Beijing 100021, Peoples R China [*1]Chinese Acad Med Sci, Dept Med Oncol, Inst Canc Hosp, 17 Panjiayuannanli, Beijing 100730, Peoples R China
推荐引用方式(GB/T 7714)：
Guo Ye,Shi Mei,Yang Ankui,et al.Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial[J].HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK.2015,37(8):1081-1087.doi:10.1002/hed.23707.
APA：
Guo, Ye,Shi, Mei,Yang, Ankui,Feng, Jifeng,Zhu, Xiaodong...&Shi, yuankai.(2015).Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial.HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK,37,(8)
MLA：
Guo, Ye,et al."Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial".HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK 37..8(2015):1081-1087

相关文献

[1]A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck [2]PD-L1 expression in recurrent or metastatic head and neck squamous cell carcinoma in China (EXCEED study): a multicentre retrospective study [3]LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy [4]The biology of combination immunotherapy in recurrent metastatic head and neck cancer [5]Genetic Polymorphisms of FCRL3, NLRP3 and IL2 are Associated with the Risk of Head and Neck Cancer in a Chinese Population [6]BAP1 Is a Novel Target in HPV-Negative Head and Neck Cancer [7]Lactate-driven type I collagen deposition facilitates cancer stem cell-like phenotype of head and neck squamous cell carcinoma [8]头颈肿瘤围术期静脉血栓栓塞症防治中国专家共识 [9]Advances in nanomaterials for the diagnosis and treatment of head and neck cancers: A review [10]Functional CYP1A1 genetic variants, alone and in combination with smoking, contribute to development of head and neck cancers

资源点击量：434 今日访问量：1 总访问量：420 更新日期：2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）